Share Name Share Symbol Market Type Share ISIN Share Description
Reneuron Group Plc LSE:RENE London Ordinary Share GB00BF5G6K95 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  2.00 1.45% 139.50 138.00 144.00 141.00 135.00 137.50 105,768 16:35:09
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 6.1 -13.9 -35.9 - 79

ReNeuron Group plc Analyst Conference Call

06/01/2021 7:00am

RNS Non-Regulatory


ReNeuron Group plc

06 January 2021

  6 January 2021      AIM: RENE.L 


ReNeuron Group plc

("ReNeuron" or the "Company")

Analyst Conference Call

ReNeuron Group plc (AIM: RENE.L), a UK-based global leader in the development of cell-based therapeutics, will host a conference call for analysts at 10.00am GMT today to discuss the Company's recent half year results, fundraising and outlook for the year ahead.

Analysts who require dial-in details, please contact Buchanan at

A recorded webcast of the analyst conference call, including investor presentation slides, will be made available during the afternoon of 6 January 2021 at this link:

The recorded webcast will also be made available at the investor centre of ReNeuron's website, .


ReNeuron                                                     +44 (0) 20 3819 8400 
Olav Hellebø, Chief Executive Officer 
Michael Hunt, Chief Financial Officer 
  Buchanan (UK Media/Investor relations)                      +44 (0) 20 7466 5000 
Mark Court, Sophie Wills, Tilly Abraham 
  Stifel Nicolaus Europe Limited (NOMAD and Joint Broker) 
  Ben Maddison, Stewart Wallace                               +44 (0) 20 7710 7600 
N+1 Singer (Joint Broker) 
 Aubrey Powell, James Moat, Hannah Woodley                    +44 (0) 20 7496 3000 

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain. The Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

January 06, 2021 02:00 ET (07:00 GMT)

1 Year Reneuron Chart

1 Year Reneuron Chart

1 Month Reneuron Chart

1 Month Reneuron Chart
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210414 01:43:07